Condition: Non-Squamous Non-Small Cell Lung Cancer · Sponsor: AbbVie
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity "when telisotuzumab adizutecan is given in combination with a fixed dose of osimertinib (Osi)or standard of care (Osi plus platinum/pemetrexed chemotherapy). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. Osi is a drug approved for the treatment of NSCLC. This study will be divided into two stages, in the first stage participants will receive increasing doses of telisotuzumab adizutecan with Osi. Participants will then be randomized into 4 groups called treatment arms where 3 groups will receive 1 of 3 doses of telisotuzumab adizutecan from from the dose escalation phase with Osi, or standard of care (Osi plus chemotherapy). In the second stage participants will receive the optimal dose of telisotuzumab adizutecan, from the previous stage, with Osi, or SOC. Approximately 854 adult participants with 1L estimated glomerular filtration rate (EGFR) mut (mutated) not sufficient quantity (NSq) NSCLC will be enrolled in the study in 200 sites worldwide. In Stage 1, during dose escalation participants will receive increasing intravenous (IV) doses of telisotuzumab adizutecan with oral Osi tablets. participants will receive 1 of 3 doses of telisotuzumab adizutecan with Osi, or standard of care (Osi plus chemotherapy). In stage 2 pa…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Ironwood Cancer and Research Centers - Chandler II /ID# 275443 | Chandler, Arizona, United States | Recruiting |
| USC Norris Comprehensive Cancer Center /ID# 275343 | Los Angeles, California, United States | Recruiting |
| Usc Norris Oncology/Hematology Treatment Center /ID# 278673 | Newport Beach, California, United States | Recruiting |
| University Colorado Cancer Center /ID# 275382 | Aurora, Colorado, United States | Recruiting |
| Mid Florida Hematology And Oncology Center /ID# 275278 | Orange City, Florida, United States | Recruiting |
| Kaiser Permanente Moanalua Medical Center /ID# 275942 | Honolulu, Hawaii, United States | Recruiting |
| The Iowa Clinic /ID# 276020 | West Des Moines, Iowa, United States | Completed |
| Nho - Revive Research Institute /ID# 276115 | Lincoln, Nebraska, United States | Recruiting |
| Renown Regional Medical Center /ID# 276049 | Reno, Nevada, United States | Recruiting |
| Texas Oncology - South Austin /ID# 276033 | Austin, Texas, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center /ID# 275107 | Houston, Texas, United States | Recruiting |
| Texas Oncology - Palestine Cancer Center /ID# 276034 | Palestine, Texas, United States | Recruiting |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07005102